XSNX · Novaccess Global Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 | Q1 '23 | Q3 '22 | Q2 '22 | Q1 '22 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | - | - | - | - |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $0 | - | - | - | - |
| Gross Profit | $0 | $0 | $0 | $0 | $0 | $0 | - | - | - | - |
| R&D | $37.3K | $36.3K | $49.7K | $40.2K | $41.0K | $35.0K | $51.1K | $8.4K | $42.4K | - |
| SG&A | $278.0K | $196.3K | $207.8K | $444.5K | $1.01M | $482.2K | $273.8K | $381.4K | $279.9K | - |
| Total Operating Expenses | $315.3K | $232.6K | $257.5K | $484.6K | $1.05M | $517.1K | $324.9K | $426.9K | $322.3K | $501.5K |
| D&A | - | - | - | - | - | - | - | - | - | $0 |
| Operating Income | ($315.3K) | ($232.6K) | ($257.5K) | ($484.6K) | ($1.05M) | ($517.1K) | ($324.9K) | ($426.9K) | ($322.3K) | ($501.5K) |
| Interest Expense | $295.1K | $106.5K | $71.8K | $295.1K | $262.2K | $300.5K | $520.9K | $255.6K | $376.2K | $10.7K |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($936.3K) | ($492.6K) | $1.30M | ($779.6K) | $453.8K | ($2.63M) | ($285.1K) | ($1.23M) | ($143.3K) | ($2.10M) |
| EPS - Basic | ($0.02) | ($0.02) | $0.06 | ($0.04) | $0.02 | ($0.14) | ($0.02) | ($0.08) | ($0.01) | ($0.16) |
| EPS - Diluted | ($0.02) | ($0.02) | $0.01 | ($0.04) | $0.01 | ($0.01) | ($0.02) | ($0.05) | - | - |
Balance Sheet
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 | Q1 '23 | Q3 '22 | Q2 '22 | Q1 '22 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $20.9K | $9.8K | $1.5K | $21.4K | $22.0K | $38.9K | $64.3K | $61.6K | $24.7K | $180.7K |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $760.2K | $636.8K | $590.5K | $514.7K | $446.8K | $443.4K | $375.7K | $161.9K | $172.7K | $143.1K |
| Current Assets | $62.2K | - | - | - | - | - | - | - | - | - |
| Total Assets | $62.2K | $85.6K | $17.3K | $62.2K | $103.5K | $58.5K | $124.9K | $83.5K | $36.0K | $208.1K |
| Current Liabilities | $10.09M | $6.94M | $6.45M | $7.86M | $5.83M | $7.08M | $4.78M | $4.52M | $3.86M | $3.97M |
| Long-term Debt | - | - | - | - | - | - | $165.9K | $165.9K | $165.9K | $165.9K |
| Total Liabilities | $10.09M | $6.94M | $6.45M | $7.86M | $5.83M | $7.08M | $4.78M | $4.68M | $4.03M | $4.14M |
| Stockholders' Equity | ($10.02M) | ($6.85M) | ($6.43M) | ($7.80M) | ($5.73M) | ($7.03M) | ($4.65M) | ($4.60M) | ($3.99M) | ($3.93M) |
| Retained Earnings | ($69.56M) | ($66.09M) | ($65.60M) | ($66.90M) | ($64.36M) | ($64.81M) | ($62.18M) | ($61.83M) | ($60.60M) | ($60.46M) |
Cash Flow
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 | Q1 '23 | Q3 '22 | Q2 '22 | Q1 '22 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($39.9K) | - | - | ($159.3K) | - | - | ($190.1K) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | $20.0K | - | - | $134.0K | - | - | $34.1K | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 | Q1 '23 | Q3 '22 | Q2 '22 | Q1 '22 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -1504.8% | -575.2% | 7518.7% | -1252.5% | 438.6% | -4494.7% | -228.3% | -1472.7% | -397.7% | -1007.6% |
| Return on equity | 9.3% | 7.2% | -20.3% | 10.0% | -7.9% | 37.5% | 6.1% | 26.7% | 3.6% | 53.4% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.01 | - | - | - | - | - | - | - | - | - |
| Quick ratio | 0.01 | - | - | - | - | - | - | - | - | - |
| Cash ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.05 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | -0.04 | -0.04 | -0.04 | -0.04 |
| Debt / Assets | - | - | - | - | - | - | 1.33 | 1.99 | 4.60 | 0.80 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -1.1x | -2.2x | -3.6x | -1.6x | -4.0x | -1.7x | -0.6x | -1.7x | -0.9x | -46.9x |
| Equity multiplier | -0.01 | -0.01 | -0.00 | -0.01 | -0.02 | -0.01 | -0.03 | -0.02 | -0.01 | -0.05 |
| Liabilities / Assets | 162.09 | 81.03 | 371.81 | 126.28 | 56.35 | 121.02 | 38.25 | 56.06 | 111.76 | 19.87 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | 2.0x | - | 17.5x | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 34.9% | 78.0% | 50.2% | -49.2% | -147.1% | -60.4% | 35.2% | -51.8% | 77.0% | -642.7% |
| Net income growth (YoY) | -20.1% | - | - | -173.5% | - | -1736.2% | 86.4% | -83.8% | - | - |
| EPS growth (YoY) | 50.0% | - | - | -100.0% | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -28.5% | -19.7% | 8.5% | -67.6% | -24.5% | -76.0% | -18.5% | -69.9% | -73.4% | -10.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2020-09-30.
Product / service
$1.04M totalCommercial$998.4K · 95.6%
Residential$46.0K · 4.4%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing NovAccess Global Inc. against the 5 most active filers in the same SIC group.